Form 4: Corbus Pharmaceuticals Director Anne Altmeyer Acquires Stock Options

Director Anne Altmeyer acquired stock options in Corbus Pharmaceuticals Holdings, Inc. on May 16, 2024.

Summary

• Anne Altmeyer, a director of Corbus Pharmaceuticals Holdings, Inc., acquired 2,783 stock options on May 16, 2024.
• The options have an exercise price of $45.92.
• The options were granted under the company's 2024 Equity Compensation Plan and will vest 100% on the one-year anniversary of the grant date.
• Following the transaction, Altmeyer directly owns 2,783 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice. The acquisition of options by a director can be seen as a slightly positive sign, indicating confidence in the company.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

There is no specific future outlook provided in this document.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in publicly traded companies as part of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates